Acadia Pharmaceuticals 2021 Annual Report

Acadia Pharmaceuticals' 2021 annual report detailing the company's performance in neuroscience and CNS disorder treatments. The report highlights NUPLAZID's $484.1 million in net sales for Parkinson's disease psychosis, advancement of late-stage programs for Alzheimer's disease psychosis, Rett syndrome, and schizophrenia, and expansion of early-stage pipeline through strategic partnerships.